Impact of life-threatening bleeds on health systems: Stewardship and implementation of a novel reversal agent

Monday, May 4th, 2020 | 12:00 pm - 1:00 pm CT

Wednesday, May 6th, 2020 | 1:00 pm - 2:00 pm CT

Please join us for an in-depth look at the impact of life-threatening Factor Xa inhibitor-related bleeds, including the clinical value and available CMS New Technology Add-on Payment (NTAP) reimbursement for a novel, specific reversal agent.

Webinar Topics:

  • Unmet need in life-threatening bleeds
  • Treatment challenges
  • Value of a novel, specific reversal agent
  • Available reimbursement for health systems




Sheldon Koenig

EVP, Chief Commercial Officer

Portola Pharmaceuticals


Jeff Myers, MD, PhD

SVP, Medical Affairs

Portola Pharmaceuticals